Luo et al. (2021) demonstrated that increased IGF2 and insulin receptor substrate 1 (IRS1) activated IGF1R/AKT/mTOR signaling and promoted trastuzumab resistance in HER2+ breast cancer. Here, IGF1R is linked to breast carcinoma.